Select a company

Go

Company Stage

  • Private (seed)
  • Private (post-seed)
  • Quoted

Sector

  • Energy and Renewables
  • IT & Communications
  • Chemicals & Materials
  • Pharma & Biotech
  • Medical Equipment & Supplies

University

  • King's College London
  • Queen Mary, University of London
  • University of Bath
  • University of Bristol
  • University of Cardiff (Fusion IP)
  • University of Glasgow
  • University of Leeds
  • University of Oxford
  • University of Sheffield (Fusion IP)
  • University of Southampton
  • University of Surrey
  • University of York
  • Other

Stakeholder

  • IP Group
  • IP Venture Fund
  • Top 10 Holdings
    by value

Search keyword

Pharma & Biotech

University: Southampton

Company Stage: Private (post-seed)

Capsant Neurotechnologies

Capsant Neurotechnologies is focused on solving problems in the discovery of novel targets and drugs for central nervous system disorders such as stroke, trauma, epilepsy, Parkinson's and Alzheimer's.

The company has a technology platform based on organotypic slice cultures. Capsant's organotypic slices have characteristics similar to the brain in vivo. As a result, the slices can be used to observe normal brain behaviour. They can also be given the characteristics of diseased brains, and this breakthrough has meant that Capsant can use the slices as screens for new drug candidates.

As at 31 Dec 2012

IP Group holding

  

49.9%

Holding represents undiluted beneficial equity interest excluding debt